Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $27.77 Consensus PT from Analysts

Travere Therapeutics, Inc. (NASDAQ:TVTX) has received an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $27.77.

Several equities analysts have recently commented on TVTX shares. Barclays boosted their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. HC Wainwright boosted their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Canaccord Genuity Group boosted their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Evercore ISI boosted their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, November 14th.

Travere Therapeutics Trading Down 6.8 %

NASDAQ TVTX opened at $21.98 on Tuesday. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $25.29. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -5.36 and a beta of 0.72. The firm’s 50 day moving average price is $19.68 and its two-hundred day moving average price is $16.63.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm had revenue of $74.79 million for the quarter, compared to analysts’ expectations of $72.38 million. Equities analysts anticipate that Travere Therapeutics will post -1.4 EPS for the current year.

Insiders Place Their Bets

In other Travere Therapeutics news, SVP William E. Rote sold 2,437 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the transaction, the senior vice president now owns 83,170 shares of the company’s stock, valued at $1,618,488.20. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Sandra Calvin sold 54,244 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at approximately $1,360,250. This represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 218,425 shares of company stock valued at $4,674,259 in the last quarter. Insiders own 3.75% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its position in shares of Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares during the last quarter. Creative Planning raised its position in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after buying an additional 995 shares during the last quarter. Semanteon Capital Management LP acquired a new position in shares of Travere Therapeutics during the third quarter valued at about $513,000. China Universal Asset Management Co. Ltd. raised its position in shares of Travere Therapeutics by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,712 shares of the company’s stock valued at $206,000 after buying an additional 5,767 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its position in shares of Travere Therapeutics by 24.4% during the third quarter. Rice Hall James & Associates LLC now owns 94,736 shares of the company’s stock valued at $1,325,000 after buying an additional 18,562 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.